Diabetes Research Articles & Analysis
50 news found
Ace Therapeutics launches its cutting-edge in vivo models of diabetes mellitus. These models—chemically induced, genetically engineered, or diet-induced—have the potential to advance diabetes research by giving scientists the means to support the identification and development of novel treatment approaches. ...
Ace Therapeutics, a leading provider of preclinical research services and products, is proud to announce the launch of its extensive suite of diabetic mouse models. These models have been specifically designed to enable research on different types of diabetes including type 1, type 2, and gestational diabetes, ...
CD BioSciences, a US-based CRO serving the global life science research community, has announced the launch of its new services to study the Mechanistic Target of Rapamycin (mTOR) in diabetes and metabolism research. ...
The prevalence of CKD due to T1D increased by 58.2% from 1990 to 2007 and by 21.7% from 2007 to 2017. “Apart from diabetes and hypertension management, there are currently very limited treatment options to slow kidney disease progression in people with chronic kidney disease and type 1 diabetes,” said Janet McGill, Professor of Medicine in the ...
ByBayer AG
Alfa Chemistry offers tofacitinib citrate as active pharmaceutical ingredients in various purities and quantities to meet the specific requirements of different research projects. The product is manufactured using advanced technology and under strict quality control procedures to ensure its safety and effectiveness. ...
Bodyport, the digital health company focused on the detection and management of heart disease, today announced that it has named Amit Rushi as Chief Commercial Officer (CCO) and Phyllis Whiteley as Chair of the Board of Directors. With this newly created role, Amit Rushi will serve as part of the executive team and prepare the organization for commercialization and growth. As Chair of the Board, ...
Over half of patients surveyed agreed that they consistently follow their healthcare providers’ recommendations for managing their diabetes. LifeScan, a world leader in blood glucose monitoring, today announced results of a new global research study, conducted by market research firm Burke, Inc., of 793 adults living with Type 2 ...
ByLifeScan
Updated 12-month results from the open-label investigator-initated Phase II clinical trial GADinLADA that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd® in individuals diagnosed with Latent Autoimmune Diabetes in Adults (LADA) were presented today at the European Association for the Study of Diabetes ...
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, has received FDA clearance of its Investigational New Drug (IND) application for a phase 2 study in Diabetic Kidney Disease (DKD) for INV-202, the Company’s lead program. Inversago scientists identified Diabetic Kidney Disease as the most ...
The striking fact drives a great deal of cardiovascular research worldwide, among which peptide development is brought into focus owing to its certain effects on the remission and prevention of diseases. BOC Sciences provides an extensive list of peptides for research on diabetes, cancers, HIV, etc. Its peptides for cardiovascular ...
BOC Sciences has been constantly enriching its peptide product library for years. Its peptides for diabetes research are recently brought into focus due to the growing concerns on this problem According to data from the WHO, a large number of adults are having diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia. ...
Diamyd Medical has contributed with study drugs, expertise and some financial support for immunological analyses and determination of HLA haplotypes. About LADA Latent Autoimmune Diabetes in Adults represents close to 10% of patients diagnosed with type 2 diabetes. LADA is characterized by an ongoing autoimmune destruction of the insulin-producing beta cells, a ...
Longenesis announced today the preliminary results from its study on Type 1 Diabetes care in partnership with Medtronic. In less than three months, more than 85 patients participated in the research study, providing qualitative and quantitative data on the quality of life for Type 1 diabetics using insulin pumps compared to daily insulin ...
The primary endpoints of safety and tolerability were met in the open-label investigator-initiated Phase II clinical trial GADinLADA, in which the diabetes vaccine Diamyd® was administered directly into the lymph node of 14 patients aged 30 to 70 years with the autoimmune form of diabetes called LADA (Latent Autoimmune Diabetes in Adults). ...
Michael Crutchlow joins Kallyope after 15 years at Merck, where he most recently served as Executive Director, Late-Stage Clinical Research – Diabetes, Endocrinology and Metabolism following positions in clinical pharmacology, experimental therapeutics and early clinical biologics development. ...
CD BioSciences, a US-based life science research product supplier and CRO, proudly offers AMPK Pathway to the life science community for researchers focusing on diabetes and metabolism study. ...
” Clinical trial diversity JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, is broadening the understanding and awareness of T1D and getting more people involved in clinical trials, screening, monitoring and research. ...
AVM Biotechnology, LLC, a clinical stage company advancing AVM0703 in the treatment of Non-Hodgkin’s Lymphoma (NHL)/Leukemia, today announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant. This $1.6 million award from the National Institute of Diabetes and Digestive Kidney Disease (NIDDK) will allow the company to ...
Camillo Ricordi and Giacomo Lanzoni at the cGMP Advanced Human Cell and Biologics Manufacturing Facility of the Cell Transplant Center at the Diabetes Research Institute, University of Miami Miller School of Medicine, we will continue to optimize the platform and generate data required to advance our therapies through clinical trials." ...
Early detection and related preventive care actions often result in significant cost-savings, too, anywhere from $8,000–$13,000 in savings per member per year (savings estimates based on customer research and analysis). In addition, considering Black Americans and Hispanics are two to three times more likely to require a diabetic amputation than others, ...